Key facts
- This page summarizes Braden M. Leonard's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Dec 2025, 18:20.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
No transaction description listed
Additional SEC filing notes
Section 16 status
Braden M. Leonard is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Footnote F2
Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold.